contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-german-customer-orders-nexstim-nbs-system-5

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Minulla ei kyllä näy viimeisimmän kierroksen summaa tai päivämäärää tuola linkin takana?

Kiitos – hyvin etsitty / löydetty! Eli 6:lta varhaisen vaiheen Venture Capital sijoittajilta on tullut (ko.lähteen mukaan) rahaa 9 M $. Kierros päättynyt 28.11.2024 (Copilot mukaan?) Aikaisempi 9 /2023 päättynyt siemenrahoitus arvo 1,5 M $ ” Sinaptica Therapeutics has raised over time = 10.5M $”

https://pitchbook.com/profiles/company/528316-48#overview tämän mukaan Sinaptican rundi olisi nyt completed

Kiitos @Mark_Renton! Nexstimin koko tiimi on tehnyt kovasti töitä tämän eteen ja hienoa nähdä sen tuloksena tällainen huikea viikko uusien tilausten osalta.

Vuoden kurssinousija Hesulissa, eikä ihan syyttä. (Joo, vähän nollapostaus, mutta Nexstim-sijoittajille ei ihan nolla-arvoinen sisältö tässäkään heitossa.)

Tämä viikko meni aika hyvin kauppojen suhteen. Onnittelut @Mikko_Karvinen_Nexst ja koko Nexstimin jengi, nyt on hyvä draivi päällä  https://www.nexstim.com/news-and-events/news/press-release/delve-psychiatry-in-nevada-united-states-orders-nexstim-nbs-5-system-1

Viime vuonna oli vuoden viime päivinä 5 vastaavaa tiedotetta, joissa taisi olla yhteensä 6 laitetta. Osa tuli tosiaan joulun välipäivinä. Aiemmin ei muistini mukaan ihan vastaavaa tykitystä ole nähty.

Nexstim

Press release, Helsinki, 19 November 2024 at 3 PM (EET) New German Customer Orders Nexstim NBS System 5Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System...

Press release, Helsinki, 19 November 2024 at 3 PM (EET)&nbsp;New German Customer Orders Nexstim NBS System 5Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new neurosurgery customer in Germany.The Nexstim Navigated Brain Stimulation (NBS) System 5 ordered includes motor mapping, speech mapping and therapy modules. The NBS System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech function. The information gained from the mapping may be used in pre-procedural planning. The therapy module allows the system to be used for the treatment of major depression and chronic neuropathic pain as CE-marked in Europe.Mikko Karvinen, CEO of Nexstim, comments: “Our neurosurgery customers in Germany compose an extensive user community. As part of our strong presence in Germany, we have for over a decade now supported the International Symposium on nTMS in Neurosurgery and Neuromodulation held in Berlin. This year the event was organized by the neurosurgery departments of Charité Berlin, Heidelberg University Hospital and the Technical University of Munich. The symposium once again attracted a wide audience, fostering collaboration in clinical and research applications not only in Germany but within nTMS users internationally.”&nbsp;Further information is available on the website&nbsp;<a href="https://www.nexstim.com">www.nexstim.com</a>, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com&nbsp;About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit <a href="http://www.nexstim.com/">www.nexstim.com </a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/dd41fc84-27c5-450e-97e5-2153a4422360/nexstim-plc-press-release-ger-order-19112024-final.pdf">Nexstim Plc_Press release_Ger order_19112024_FINAL.pdf</a></div> </div>

Stay up to date with our newsletter